Tradestie Institutional Equity Comparison Engine

BVS vs VVOS โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

BVS Overall Edge

BVS Captures Institutional Edge (4โ€“0 Pillars ยท 9โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Bioventus Inc. Class A Common Stock (BVS) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, BVS trades at 11.1x Forward P/E with 10.1% operating margin (+2.7% YoY revenue) versus VVOS at N/M Forward P/E and -107.9% operating margin (+34.9% YoY). In options structure, BVS sits in BREAKDOWN (100th %ile IV; Dealer Gamma Walls on Pro) against VVOS sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner BVS
BVS 11.1x vs VVOS N/M Fwd P/E
Growth & Margin Winner BVS
Op Margin 10.1% vs -107.9% ยท YoY +2.7% vs +34.9%
Momentum & Technical Winner BVS
1Y +47.0% vs -97.7% ยท 52W Pos 36% vs 0%
Options & Structure Winner BVS
BREAKDOWN (100th %ile IV) vs BREAKDOWN (N/A IV)
BVS NASDAQ
Bioventus Inc. Class A Common Stock
Surgical & Medical Instruments & Apparatus
$9.88
-0.7% 1D
Market Cap $681.3M
1M Return -34.31%
1Y Return +47.02%
Forward P/E 11.1x
Unified AI Score
46.2 / 100 HOLD
Tech 35.0 Fund 49.0 Flow 64.0 Mom 55.0
VVOS NASDAQ
Vivos Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.05
-5.1% 1D
Market Cap $1.9M
1M Return -59.25%
1Y Return -97.71%
Forward P/E N/M
Unified AI Score
36.4 / 100 SELL
Tech 25.0 Fund 35.0 Flow 50.0 Mom 30.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: BVS +47.02% VVOS -97.71% Spread: +144.73 pp (BVS Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period BVS Revenue VVOS Revenue BVS Op. Margin VVOS Op. Margin Margin Edge
FY2019 $340M $10M 9.2% -92.8% BVS
FY2020 $320M $10M 6.6% -92.1% BVS
FY2021 $430M $20M 2.8% -120.7% BVS
FY2022 $510M $20M -32.7% -156.2% BVS
FY2023 $510M $10M -16.0% -125.3% BVS
FY2024 $570M $20M -2.7% -74.3% BVS
FY2025 $570M $20M 9.5% -114.1% BVS

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: BVS (9) vs VVOS (1)
Institutional Metric BVS VVOS Criterion Row Winner
Market Capitalization Scale $681.3M $1.9M Larger Scale BVS
Trailing P/E Ratio Valuation 12.3x N/M Lower Multiple BVS
Forward P/E Ratio Valuation 11.1x N/M Lower Multiple BVS
Revenue Growth (YoY) Growth +2.7% +34.9% Higher Growth VVOS
Operating Margin (TTM) Profitability 10.1% -107.9% Higher Margin BVS
Net Profit Margin Profitability 9.8% -121.8% Higher Margin BVS
Return on Equity (ROE) Capital Efficiency 25.8% -8585.3% Higher ROE BVS
52-Week Range Position Momentum 36% ($6โ€“$16) 0% ($0โ€“$3) Stronger Trend BVS
Beta / 30D Volatility Risk Regime 0.85ฮฒ ยท 74% Vol 1.70ฮฒ ยท 111% Vol Lower Realized Risk BVS
Unified Institutional Score Composite Signal 46.2 / 100 (HOLD) 36.4 / 100 (SELL) Higher Composite BVS

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full BVS vs VVOS Buy Guide
BVS BREAKDOWN
76d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 100th %ile
IV Regime Extreme (>80th %ile)
Live BVS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
VVOS BREAKDOWN
113d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live VVOS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither BVS nor VVOS registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.